FDA clarifies stricter stance on GLP-1 compounding: Reuters

Hims, historically seen as one of the largest sellers of copycat GLP-1s, sunk on the news.

Source: Sherwood News.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *